设为首页收藏本站

中国病毒学论坛|我们一直在坚持!

 找回密码
 立即注册

QQ登录

只需一步,快速开始

搜索
热搜: 活动 交友 discuz
查看: 1024|回复: 0
打印 上一主题 下一主题

[转移帖]Science:能与2种不同抗原结合的单抗(Genentech新成果)

[复制链接]

2359

帖子

1831

学分

10万

金币

管理员

Rank: 9Rank: 9Rank: 9Rank: 9

积分
1831
QQ
跳转到指定楼层
楼主
发表于 2015-9-9 12:58:10 | 只看该作者 回帖奖励 |倒序浏览 |阅读模式
原始帖由论坛会员kousyouki发表于 2009-3-28 02:04


专题:Science报道

美国科学家近日通过研究,打破了一个古老的免疫学教条——一个抗体只能结合到一个抗原上。他们成功地使一个抗体紧密地结合到两个不同的抗原上。相关论文发表在3月20日的《科学》杂志上。

这一抗体作用于2种蛋白——血管内皮生长因子(VEGF)和人类表皮生长因子受体2(HER2),前者被认为会促进肿瘤的生长,而后者则在一些侵略性的乳腺肿瘤里高表达。

科学家以前经常发现一些抗体能够松散地结合到多个抗原上,但一直没有发现或通过操作实现单个抗体特异性地紧密结合到2个不同抗原上。

在此次研究中,美国加州基因技术公司(Genentech)的Germaine Fuh和同事突变了HER2的抗体,然后在突变体中筛选出了能够同时结合HER2和VEGF的变异。这是首次创造出能结合到2种无关联蛋白的抗体。Fuh说:“这将开启双重标靶型疗法之门。”

重点研发抗体疗法的Genmab生物技术公司副总裁Paul Parren表示,结果令人吃惊。他说:“我们以前根本没有这样考虑过抗体,它让人不禁要猜测,这种分子是否也有可能在自然界中存在。”(生物谷Bioon.com)

生物谷推荐原始出处:

Science 20 March 2009OI: 10.1126/science.1165480

Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site

Jenny Bostrom,1,2 Shang-Fan Yu,3 David Kan,3 Brent A. Appleton,1 Chingwei V. Lee,1,2 Karen Billeci,4 Wenyan Man,1 Franklin Peale,5 Sarajane Ross,3 Christian Wiesmann,1 Germaine Fuh1,2*

The interface between antibody and antigen is often depicted as a lock and key, suggesting that an antibody surface can accommodate only one antigen. Here, we describe an antibody with an antigen binding site that binds two distinct proteins with high affinity. We isolated a variant of Herceptin, a therapeutic monoclonal antibody that binds the human epidermal growth factor receptor 2 (HER2), on the basis of its ability to simultaneously interact with vascular endothelial growth factor (VEGF). Crystallographic and mutagenesis studies revealed that distinct amino acids of this antibody, called bH1, engage HER2 and VEGF energetically, but there is extensive overlap between the antibody surface areas contacting the two antigens. An affinity-improved version of bH1 inhibits both HER2- and VEGF-mediated cell proliferation in vitro and tumor progression in mouse models. Such "two-in-one" antibodies challenge the monoclonal antibody paradigm of one binding site, one antigen. They could also provide new opportunities for antibody-based therapy.

1 Department of Protein Engineering, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
2 Department of Antibody Engineering, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
3 Department of Translational Oncology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
4 Department of Assay and Automation Technology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
5 Department of Pathology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
分享到:  QQ好友和群QQ好友和群 QQ空间QQ空间 腾讯微博腾讯微博 腾讯朋友腾讯朋友
收藏收藏 分享分享 支持支持 反对反对
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

QQ|论坛App下载|Archiver|小黑屋|中国病毒学论坛    

GMT+8, 2024-6-16 20:16 , Processed in 0.093255 second(s), 29 queries .

Powered by Discuz! X3.2

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表